Australia markets open in 8 hours 11 minutes
  • ALL ORDS

    7,082.20
    -58.80 (-0.82%)
     
  • AUD/USD

    0.6317
    +0.0011 (+0.17%)
     
  • ASX 200

    6,890.20
    -53.20 (-0.77%)
     
  • OIL

    86.34
    -2.89 (-3.24%)
     
  • GOLD

    1,834.60
    -6.90 (-0.37%)
     
  • Bitcoin AUD

    43,329.72
    +64.80 (+0.15%)
     
  • CMC Crypto 200

    582.95
    -1.20 (-0.21%)
     

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

NEWPORT BEACH, Calif., February 22, 2023--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13736592. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005270/en/

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Media Contact:
Email: media@evolus.com